middle.news
Lumos Diagnostics Hits Halfway Mark in FebriDx CLIA Waiver Study, Eyes $1B US Market
11:45pm on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Lumos Diagnostics Hits Halfway Mark in FebriDx CLIA Waiver Study, Eyes $1B US Market
11:45pm on Monday 2nd of June, 2025 AEST
Key Points
61 of 120 bacterial positive patients enrolled, marking 50% recruitment milestone
Total patient enrollment at 439, nearing 500-patient milestone triggering $298,457 BARDA payment
Study expected to complete by Q4 2025 with FDA CLIA waiver application planned for October
Successful CLIA waiver could open access to a US market exceeding $1 billion
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Lumos Diagnostics Holdings (ASX:LDX)
OPEN ARTICLE